Research programme: neoantigen-based cancer immunotherapeutics - Gritstone Oncology/Immune Design

Drug Profile

Research programme: neoantigen-based cancer immunotherapeutics - Gritstone Oncology/Immune Design

Alternative Names: multi-genome ZVex; ZVex-Neo; ZVexMulti

Latest Information Update: 15 Nov 2016

Price : $50

At a glance

  • Originator Gritstone Oncology; Immune Design
  • Developer Gritstone Oncology
  • Class Antineoplastics; Cancer vaccines; Immunoproteins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Non-small cell lung cancer

Most Recent Events

  • 11 Nov 2016 Preclinical trials in Non-small cell lung cancer in USA (Parenteral)
  • 09 May 2016 Immune Design and Gritstone plan a clinical trial in Non small cell lung cancer
  • 09 May 2016 Gritstone Oncology and Immune Design enter a research collaboration to develop neoantigen-based cancer immunotherapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top